


NRG Oncology Semiannual Meeting

SUMMER 2026 SYMPOSIUM

Ovarian Cancer Prevention is Our Duty: When We Fail—Recurrence Mitigation and Treatment Strategies for Ovarian Cancer

Thursday, July 16, 2026
8 am - 12: 15 pm MT - Denver, CO



Program Booklet

***Ovarian Cancer Prevention is Our Duty:
When We Fail—Recurrence Mitigation and Treatment Strategies for Ovarian Cancer***
July 16, 2026
Denver, Colorado

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any **ineligible company** * (formally known as commercial interests). **All Committee/Planning/Faculty members** were required to disclose all financial relationships and speakers were required to disclose any financial relationship **as it pertains to the content of the presentations**.

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. "Relevant" financial relationships are financial transactions (in any amount) occurring within the **past 24 months** that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

NEW TERM *An "**ineligible company**" is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

LAST NAME	FIRST NAME	Individual's Role(s) in Activity	Name of Ineligible Company(s)	Nature of Relevant Financial Relationship(s)
<i>Planning Disclosures</i>				
Matulonis, MD	Ursula	Planner	Whitehawk; AstraZeneca; Symphogen; MacroGenics; AbbVie; Corcept; Nextcure; Ascendis; Merck; DayOne Bio	Consultant (Whitehawk) Data Safety Monitoring Board (AstraZeneca; AbbVie; Corcept; Symphogen; MacroGenics) Advisory Board (Nextcure; Ascendis; Merck; DayOne Bio)
Walker, MD	Joan	Planner	Nothing to Disclose	
<i>Speaker Disclosures</i>				
Belcher, MD	Angie	Speaker	Cision-Vision	Co-Founder
Coleman MD	Robert	Speaker	BioNTech; BMS; BeOne; Lilly; Pharma&; Genentech/Roche; AstraZeneca; GenMab; Pfizer; Immunogen; AbbVie; Merck; Daiichi Sankyo; Gilead/Tubulis; Eisai; Panavance; GSK; Karyopharm; TORL; Incyte; Regeneron; Faeth	Consultant/Advisory Role (BioNTech; BMS; BeOne; Lilly; Pharma&; Genentech/Roche; AstraZeneca; GenMab; Pfizer; Immunogen; AbbVie; Merck; Daiichi Sankyo; Gilead/Tubulis; Eisai; Panavance; GSK; Karyopharm; TORL; Incyte; Regeneron; Faeth) Research Funding (AstraZeneca; AbbVie; Karyopharm; Merck; GSK; Genentech/Roche; Genmab; Pharma&
Corr, MD	Bradley	Speaker	GSK; AbbVie	Advisor
Drapkin, MD	Ronny	Speaker	Moderna Tx, Inc	Contracted Research
Eskander, MD	Ramez	Speaker	AstraZeneca; MSD; Regeneron; PMV Pharmaceuticals; Daiichi Sanyo; GSK;	Honoraria (AstraZeneca; MSD; Regeneron; PMV Pharmaceuticals;

FACULTY DISCLOSURE INFORMATION

			Myriad; Seagen; AbbVie; Pfizer; Novocure; BioNTech; Mersana; Nuvectis Pharma; GSK; Merck; Loxo @ Lilly; Genmab/Seagen; Clovis Oncology; Acrivon therapeutics; Zentalis; Eisai; Gilead; Roche	Daiichi Sanyo; GSK; Myriad; Seagen; AbbVie; Pfizer; Novocure; BioNTech; Eisai; Roche; Mersana) Research Funding (Nuvectis Pharma; GSK; Merck; Daiichi Sankyo; Loxo @ Lilly; AstraZeneca; Genmab/Seagen; Clovis Oncology; Acrivon therapeutics; Zentalis; Eisai; Gilead; Roche)
Konecny, MD	Gottfried	Speaker	Abbvie; AstraZeneca; Foundation Medicine; Corcept; Torl Biotherapeutics; Merck; Lilly	Speaker (Abbvie; AstraZeneca; Foundation Medicine; Corcept) Travel Support (Torl Biotherapeutics) Reaearch Funding to Institution (Merck; Lilly)
Liu, MD	Joyce	Speaker	Bristol-Myers Squibb; Genmab	Consulting
Mathews, MD	Cara	Speaker	AADI; AbbVie; Artios; Astellas Pharma; AstraZeneca; Avenge Bio; Context Therapeutics; Deciphera; Debio; Elucida; EMD Serono; Genentech; Genmab; GSK; Immunogen; Merck; Moderna; Novocure; NCI; Pfizer; ProfoundBio; Regeneron; Repare; Seagen; Volastra; Zentalis; Daiichi Sankyo; GOG Foundation; GSK	Research Funding (AADI; AbbVie; Artios; Astellas Pharma; AstraZeneca; Avenge Bio; Context Therapeutics; Deciphera; Debio; Elucida; EMD Serono; Genentech; Genmab; GSK; Immunogen; Merck; Moderna; Novocure; NCI; Pfizer; ProfoundBio; Regeneron; Repare; Seagen; Volastra; Zentalis) Advisory Roles (AbbVie; Daiichi Sankyo) Other Relationships (GOG Foundation; GSK)
Ring, MD	Kari	Speaker	Ethicon	Speakers Bureau
Shih, MD	Le-Ming	Speaker	Nothing to Disclose	
Simpkins, MD	Fiona	Speaker	Nothing to Disclose	
Stone, MD	Rebecca	Speaker	Pacira Pharmaceuticals	Researcher
Rush	Heather	Staff	Nothing to disclose	
Shumaker	Kara	Reviewer/Staff	Nothing to disclose	
Small, MPH	Michelle N	Reviewer/Staff	Nothing to disclose	
Alvarez Secord, MD	Angeles	Reviewer/Edu-Chair	AbbVie; Aravive; AstraZeneca; Daiichi Sankyo; Ellipses Pharma; Genmab; GSK; Immunogen; Karyopharm; Merck; Mersana; Myriad; Oncoquest/Canaria Bio; Oncoquest; Roche/Genentech; TORL Biotherapeutics; Zentalis; Foundation Medicine; Gilead; Histosonics; Medtronic; Porject Nana; Up to Date; SGO; FWC; GOG Foundation; Amgen; Johnson & Johnson	Research funds to Institution (AbbVie; Aravive; AstraZeneca; Daiichi Sankyo; Ellipses Pharma; Genmab; GSK; Immunogen; Karyopharm; Merck; Mersana; Myriad; Oncoquest/Canaria Bio; Oncoquest; Roche/Genentech; TORL Biotherapeutics; Zentalis) Honorarium (Merck; GSK) Advisory Board with Honoraria (AbbVie; AstraZeneca; Daiichi Sankyo; Foundation Medicine; GSK; Genmab; Gilead; Histosonics; Medtronic; Merck) Medical Advisory Board (Porject Nana) Steering Committee Uncomp. (Oncoquest; Genmab) Royalties (Up to Date) Board of Directors (SGO; FWC; GOG Foundation) Stock-Divested in June 2024 (Amgen; Johnson & Johnson)
Duska, MD	Linda	Reviewer/Edu-Co-Chair	Merck; Corcept	Honoraria (Merck) Speakers Bureau (Corcept) Research Funding (Merck)
Gien, MD	Lilian	Reviewer	Glaxo Smith Kline; Merck; Abbvie; AstraZeneca	Speaker Honoraria (Glaxo Smith Kline; Merck) Advisory Board (Abbvie; AstraZeneca)
Blank, MD	Stephanie	Reviewer	American Board of Obstetrics and Gynecology; Merck; AstraZeneca;	Leadership (American Board of Obstetrics and Gynecology)

FACULTY DISCLOSURE INFORMATION

			GlaxoSmithKline; Pfizer; Seattle Genetics/Astellas; Acrivon; Zentalis; NX Development Corp.	Research Funding (Merck; AstraZeneca; GlaxoSmithKline; Pfizer; Seattle Genetics/Astellas; Acrivon; Zentalis; NX Development Corp.)
Mutch, MD	David	Reviewer	Nothing to disclose	
Zweizig, MD	Susan	CME Workshop Chair/Reviewer	Nothing to disclose	

CONTINUING MEDICAL EDUCATION (CME)

Accreditation Statement

The GOG Foundation, Inc. is accredited by the ACCME to provide Continuing Education for physicians.

AMA PRA Category 1 Credits™

The GOG Foundation, Inc. designates this live activity for a maximum of **4.25 AMA PRA Category 1 Credits™**.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The GOG Foundation Inc. Continuing Education (CME) Program Mission Statement

The purpose of The GOG Foundation, Inc. CME program is to provide and promote an infrastructure dedicated to enhancing the knowledge base of meeting participants and guests centered on the development, execution, analysis and application of GOG-supported clinical trials. To that end, the CME Program engages in these discussions member researchers and invited clinicians committed to reducing the risk and improving outcomes for women at risk for or afflicted with a gynecologic malignancy.

Disclosure Declaration

In compliance with ACCME regulations, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. All reported conflicts are managed by a designated official to ensure a bias-free presentation. Please see the complete disclosure list included with this program.

Off-Label Statement

Some of the presentations and discussions in this session may include the off-label use of products/devices.



How do I collect CME Certificates?

- **Evaluation Link will be emailed to all Symposium Attendees at the end of the session.**



- **OR Scan QR code** above to complete evaluation.
- **Complete Form/Click submit** and your certificate will automatically be emailed to you.

CME Evaluations must be submitted by: **August 18, 2026**

If you have issues accessing your certificate or questions about CMEs, please contact: cmeinfo@gog.org.

Slide Presentations

A PDF version of all final slide presentations are available in the Symposium Session content on the Attendee Hub and the Meeting App

For questions or comments about this CME activity, please contact: Michelle N. Small, MHA
Dir, Education Programs/CME Compliance
at msmall@gog.org

SUMMER SYMPOSIUM

**OVARIAN CANCER PREVENTION IS OUR DUTY, WHEN WE FAIL:
RECURRENCE, MITIGATION AND TREATMENT STRATEGIES
FOR OVARIAN CANCER**

July 16, 2026 | 8:00am – 12:15pm MT

Program Chairs: Ursula Matulonis, MD and Joan Walker, MD

PROGRAM DESCRIPTION:

The Summer 2026 Educational Symposium will target and address topics in ovarian cancer that are particularly challenging such as early detection and prevention, incorporating new therapies into treatment of patients with advanced ovarian cancer such as antibody drug conjugates, and treatment of platinum resistant and refractory ovarian cancer.

TARGET AUDIENCE:

This educational activity is directed towards members and non-members including our broad audience of physicians, research staff, new investigators, clinical research associates, basic researchers, medical physics, clinical trial nurses, patient advocates and other health care professionals interested in the treatment of cancer.

LEARNING OBJECTIVES: Following this activity, participants will be better able to:

- Develop a basic knowledge of early detection tests for ovarian cancer and trial results.
- Explain the rationale for opportunistic salpingectomy and its role in ovarian cancer risk reduction.
- Describe the evidence supporting new therapeutic interventions for both newly diagnosed ovarian cancer as well as recurrent cancer.
- Discuss the strategies for treatment of platinum resistant and refractory cancer.

SYMPOSIUM AGENDA		
7:00 am – 8:00 am	Breakfast Buffet	
8:00 am	Welcome/Opening Remarks	Stephanie Blank, MD
8:05 am	Symposium Introduction	Joan Walker, MD and Ursula Matulonis, MD
8:10 am	Session 1: Empower to Prevent: Steps to Eradicate Ovarian Cancer	Moderator: Joan Walker, MD Session Introduction
8:10 – 8:25 am	Universally Fast & Familial: The New Standard for Ovarian Cancer Screening	Kari Ring, MD
8:26 – 8:41 am	Event Horizon of Population-Level Ovarian Cancer Prevention	Rebecca Stone, MD
8:42 – 9:02 am	STIC-ing it to Cancer: Creative Clinical Trial Design and Interactive Panel Discussion	Joan Walker, MD Ronnie Drapkin, MD, PhD le-Ming Shih, MD, PhD
9:03 – 9:18 am	BioEngineering the End of Ovarian Cancer	Angie Belcher, PhD
9:19 – 9:35 am	Panel Discussion with Q/A with Audience Response	ALL
9:35 am	Session 2: Catch the ADC Wave	Moderator: Ursula Matulonis, MD - Session Introduction
9:37 – 9:52 am	Start Early with Smart Bombs: Precision Medicine for First-Line Treatment	Joyce Liu, MD
9:53 – 10:07 am	Precision Payloads to Target Recurrence	Ramez Eskander, MD
10:08 – 10:24 am	Precision without the Punch: Handling ADCs with Care	Brad Corr, MD
10:25 – 10:40 am	Panel Discussion with Q/A with Audience Response	ALL
10:40 – 11:00 am	Coffee Break	
11:00 am	Session 3: Beyond ADCs: New Treatment Strategies for Ovarian Cancer	Moderators: Joan Walker, MD, Ursula Matulonis, MD and Fiona Simpkins, MD, PhD Session Introduction
11:02 - 11:17 am	Turning Replication Stress into a PROC Lethal Weapon	Fiona Simpkins, MD
11:18 – 11:33 am	Exploiting Chromosomal Instability in PROC with KIF	Cara Mathews, MD
11:34 – 11:49 am	The Platinum Rechallenge Roadmap in Recurrent Ovarian Cancer	Robert Coleman, MD
11:50 – 12:05 pm	LGSOC: The Clamp and What's Next	Gottfried Konecny, MD
12:06 – 12:15 pm	Panel Discussion with Q/A: The ROC Navigation Plan: Mapping the Best Treatment Route	ALL
12:15 pm	Closing Remarks	

PROGRAM CHAIRS



Ursula Matulonis, MD

Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine, Harvard Medical School
Co-leader, GYN program, Harvard Cancer Consortium

Ursula A. Matulonis, MD is Chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. She is the first recipient of the Brock-Wilson Family Chair at the Dana-Farber Cancer Institute. She co-leads the Gynecologic Cancer Program within the Harvard Cancer Consortium and the Ovarian Cancer Specialized Program in Research Excellence (SPORE) grant from the National Cancer Institute. Her research focuses on developing new targeted therapies for gynecologic malignancies, with a specific interest in ovarian cancer and endometrial cancer.

Dr. Matulonis has led several PARP inhibitor, anti-angiogenic agent, immunotherapy, and combination trials for ovarian cancer in the United States and internationally. Dr. Matulonis serves on the Massachusetts Ovarian Cancer Task Force, chairs the Gyn subcommittee of the Alliance cooperative group, and the Scientific Advisory Board for the Ovarian Cancer Research Alliance, the Rivkin Foundation, the Clarity Foundation, and Overcome. She has received the Dana-Farber Dennis Thompson Compassionate Care Scholar award, the Lee M. Nadler "Extra Mile" Award, the Clarity Foundation award, the Zakim Award at Dana-Farber for patient advocacy, and recently in 2020, the Albany Medical College Alumni Association Distinguished Alumna Award. She has been named one of Boston's Best Physicians in Medical Oncology by Boston Magazine numerous times. Dr. Matulonis is also a recipient of grant funding from the Breast Cancer Research Foundation examining differences between ovarian cancer, endometrial cancer and breast cancer.

After receiving her MD from Albany Medical College, she completed an internship and residency at the University of Pittsburgh, followed by a medical oncology fellowship at Dana-Farber Cancer Institute in Boston, MA.



Joan Walker, MD

Assoc Director, Stephenson Cancer Center, for Belonging and Inclusivity
Louise and Clay Bennett Chair for Cancer
Professor, Gynecologic Oncology

Dr. Walker is a gynecologic oncologist who has long focused her attention on cancer prevention in GOG and NRG NCORP Research Base. She currently works on SOROCK (salpingectomy for BRCA 1 women) and has led many clinical trials (GOG 252, LAP2, 9803, 9804, GOG 237). Today we are trying to create momentum for prevention of ovarian cancer and not wait for clinical symptoms. All women need their fallopian tubes removed at completion of childbearing and genetic testing should be considered for all. STIC lesion management must be standardized, and we will discuss the design of a prospective trial to operationalize our goals.

SPEAKERS



Angie Belcher, MD

Dr. Belcher is a biological and materials engineer with expertise in the fields of biomaterials, biomolecular materials, organic-inorganic interfaces and solid-state chemistry and devices. Her primary research focus is evolving new materials for energy, electronics, the environment, and medicine. She received her B.S. in Creative Studies from The University of California, Santa Barbara. She earned a Ph.D. in inorganic chemistry at UCSB. Following with her postdoctoral research in electrical engineering at UCSB. She now holds the James Mason Crafts Professor of Biological Engineering and Materials Engineering at MIT. She is faculty in the Department of Biological Engineering, Materials Science and Engineering and the Koch Institute of Integrative Cancer Research. She teaches undergraduate subjects in material sciences and engineering and biological engineering. In 2002, she founded the company Cambrios Technologies, Inc., and in 2007 she founded Siluria Technologies, Inc. In 2020, she founded 3 companies, Cision Vision, Gensaic Therapeutics, and 6x6 Biotechnologies. Some recent awards include the Lemelson-MIT Prize for her inventions, Eni Prize for Renewable and Non-Conventional Energy, in 2009 Rolling Stone Magazine listed her as one of the top 100 people changing the country. In 2007, Time Magazine named her a "Hero" - for her research related to Climate Change. She received the Four Star General Recognition Award (US Army) for significant contribution to army transformation. In 2000, she was awarded the Presidential Early Career Award in Science and Engineering (PECASE). She was named Research Leader of the Year by Scientific American, and is a MacArthur Fellow, a Packard Fellow, an Alfred P. Sloan Fellow, a Bose Fellow, a member of American Academy of Arts and Sciences, a member of the National Academy of Inventors, a member of the National Academy of Engineering and a member of the National Academy of Sciences. In 2024, she was presented the National Medal of Science. For information about her research, here's a link to a TED video and from the NOVA series "Making Stuff":

[Prof. Angela Belcher- TED Talk, January 2011 Presentation by \\$500,000 Lemelson-MIT Prize Winner, Dr. Angela Belcher Better batteries through biology The Story of Dr. Angela Belcher AACR Annual Meeting- Dr. Angela Belcher Plenary Speech Innovation Perspectives: Angela Belcher Mildred L. Dresselhaus Lecture November 2023 Making Stuff: Wilder](#)



Robert Coleman, MD, FACOG, FACS

GOG Partners, Special Advisor to the President
GOG Foundation, Vice President
Texas Oncology, US Oncology Network

Dr. Coleman completed his Obstetrics & Gynecology residency at Northwestern University Medical Center in Chicago, Illinois, and completed his fellowship at The University of Texas MD Anderson Cancer Center in 1993. From 1993-1996, he served as Assistant Professor at Creighton University followed by service as Vice-Chairman, Department of Obstetrics and Gynecology at the University of Texas, Southwestern Medical Center. Dr. Coleman joined as Faculty at MD Anderson Cancer center in 2004 and served as Professor and Executive Director for Cancer Network Research, holding the Ann Rife Cox Chair in Gynecology.

SPEAKERS

Coleman Bio Continued

Dr. Coleman completed his Obstetrics & Gynecology residency at Northwestern University Medical Center in Chicago, Illinois, and completed his fellowship at The University of Texas MD Anderson Cancer Center in 1993. From 1993-1996, he served as Assistant Professor at Creighton University followed by service as Vice-Chairman, Department of Obstetrics and Gynecology at the University of Texas, Southwestern Medical Center. Dr. Coleman joined as Faculty at MD Anderson Cancer center in 2004 and served as Professor and Executive Director for Cancer Network Research, holding the Ann Rife Cox Chair in Gynecology.

In March 2020, he joined US Oncology Research (USOR) as Chief Scientific Officer and served briefly as Chief Medical Officer for Sarah Cannon Research Institute (SCRI). He practices at Texas Oncology, US Oncology Network and currently serves as Chief Medical officer for Vaniam Group. He also serves as Vice President, GOG Foundation and is Special Advisor to the President for GOG Partners. Dr. Coleman has authored or coauthored over 800 scientific publications, including over 470 peer-reviewed articles, along with numerous book chapters, monographs, invited articles, and textbooks. He was the 2019 APGO-CREOG awardee for Excellence in Teaching. He serves as Vice President of GOG-Foundation, Inc. He served as President of SGO (2015-2016) and President of IGCS (2020-2022). He was recently inducted into MJH Life Sciences™ 2020 class of "Giants in Cancer Care®."



Bradley Corr, MD

Katie Taylor Memorial Endowed Chair in Gynecologic Oncology
Director of Clinical Research for Gynecologic Oncology
University of Colorado School of Medicine
Department of Obstetrics and Gynecology
Division of Gynecologic Oncology

Dr. Corr is an Associate Professor of Gynecologic Oncology at the University of Colorado. He completed his residency at the Hospital of the University of Pennsylvania and his fellowship at the University of Colorado. His academic and scientific career is dedicated to improving outcomes and patient care for women with gynecologic malignancies. He is a board-certified Gynecologic Oncologist by training, and his areas of interest are early-phase clinical trials and developmental therapeutics in endometrial and ovarian cancer. He currently serves as the Director of clinical research for the Division of Gynecologic Oncology at the University of Colorado Anschutz Medical Campus. He also holds the Katie Taylor Memorial Endowed Chair in Gynecologic Oncology.

Within his institution he serves as the Deputy Director of the Lead Academic Participating Site (LAPS) grant, chief gynecologic oncology investigator in the Phase I research division, as well as the lead gynecologic oncologist in the Women's Cancer Developmental Therapeutics (WCDDT) program at the University of Colorado. Nationally he serves as the vice chair of the phase I subcommittee of the developmental therapeutics committee of the NRG. He currently is awarded as an NRG/GOG scholar and holds an NIH/NCI R01 award evaluating combination CLK/DYRK inhibition with PARP inhibition in platinum resistant ovarian cancer. He has served as the local, national, and international PI on a multitude of clinical trials with sponsorship from the NIH/NCI, industry, and investigator initiated. Dr. Corr is a clinical trialist and physician scientist with specific interest in the Wnt pathway.

SPEAKERS



Ronny Drapkin, MD, PhD

Franklin Payne Professor of Pathology
In Obstetrics & Gynecology
University of Pennsylvania

Dr. Ronny Drapkin is the Franklin Payne Professor of Pathology in Obstetrics & Gynecology at the University of Pennsylvania, where he directs the Penn Ovarian Cancer Research Center, the Gynecologic Cancer Research Program at the Basser Center for BRCA and co-directs the Ovarian Cancer Translational Center of Excellence at the Abramson Cancer Center. His research focuses on the pathogenesis and molecular evolution of women's cancers, with an emphasis on ovarian and endometrial carcinomas. His laboratory played a pivotal role in the identification of the fallopian tube epithelium as the origin of most high-grade serous ovarian cancers—a discovery that transformed the field and redefined prevention and early detection strategies. His group develops innovative model systems to study disease initiation, progression, and tumor-microenvironment interactions and is leading efforts to build a precancer atlas to identify biomarkers and therapeutic targets for cancer interception.

Dr. Drapkin trained at the Brigham and Women's Hospital and the Dana-Farber Cancer Institute and previously served on the Harvard faculty before he was recruited to the University of Pennsylvania. He is an elected member of the American Society for Clinical Investigation (ASCI) and the Association of American Physicians (AAP) honor societies and has received numerous awards including the Innovation Award from the Society of Gynecologic Oncology, the Distinguished Alumni Award from Rutgers University, and the Rosalind Franklin Prize for Excellence in Cancer Research from the Ovarian Cancer Research Foundation, among others.



Ramez Eskander, MD

Julie St. John Endowed Chair in Gynecologic Oncology
Professor, Department of Obstetrics, Gynecology and Reproductive Sciences
Clinical Trials Office Medical Director
Fellowship Director - Gynecologic Oncology
UC San Diego Health
Rebecca and John Moores NCI Designated Comprehensive Cancer Center

Ramez Eskander, MD, is a board-certified gynecologic oncologist who specializes in the comprehensive management of female reproductive system cancers, including ovarian, uterine, cervical, vulvar and vaginal cancer. His expertise includes diagnostic and therapeutic procedures, state-of-the-science treatment strategies, as well as minimally invasive (robotic) surgery, hyperthermic intraperitoneal chemotherapy (HIPEC) and novel drugs. Dr. Eskander is also experienced in developing and leading national and international clinical trials, with an aim to provide individuals with access to innovative medicines during their treatment.

SPEAKERS

Eskander Bio Continued

As an professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences, Dr. Eskander instructs medical students, residents, and fellows at UC San Diego School of Medicine. He is also the gynecologic oncology fellowship director. Dr. Eskander's research focuses on immunotherapy, targeted therapies, new combinatorial treatment approaches and a better understanding of the implications of molecular tumor testing on treatment outcomes.

Dr. Eskander has co-authored over 100 peer-reviewed articles, several book chapters and is the co-editor of Gynecologic Oncology: A Pocketbook. He speaks frequently at annual medical conferences and his work has been published in journals such as Journal of Clinical Oncology, Obstetrics and Gynecology, Gynecologic Oncology and Clinical Cancer Research, among others. In 2015, he was awarded the Society of Gynecologic Oncology's John L. Lewis Jr. Presidential Award for most influential scientific paper.

Prior to joining UC San Diego Health, Dr. Eskander was an assistant professor in the Department of Obstetrics and Gynecology at UC Irvine School of Medicine, also caring for patients with gynecologic cancers.

Dr. Eskander completed a fellowship in gynecologic oncology at UC Irvine School of Medicine and a residency in obstetrics and gynecology at UC San Diego School of Medicine, where he also earned his medical degree. He is board-certified in obstetrics and gynecology and gynecologic oncology.

Dr. Eskander is a member of many professional organizations, and is also a member of GOG-Partners, the leading national organiz



Gottfried Konecny, MD

Professor of Medicine/Oncology
David Geffen School of Medicine at UCLA
University of California Los Angeles

Dr. Konecny is Professor of Medicine and Obstetrics/Gynecology in the Divisions of Hematology/Oncology and Gynecologic Oncology at the David Geffen School of Medicine at the University of California Los Angeles. He directs the Medical Gynecologic Oncology Program at the University of California Los Angeles and heads the Drug Development Program for Gynecologic Oncology in the Translational Oncology Research Lab at the University of California Los Angeles. He completed his residency training in Obstetrics and Gynecology at the University of Munich, Germany, has completed postdoctoral studies in the laboratory of Dennis J. Slamon at the University of California Los Angeles and completed his Gynecologic Oncology Fellowship training at Mayo Clinic, Rochester, Minnesota. His ongoing research interests include drug discovery and novel therapeutics for ovarian, uterine, and cervical cancer and clinical trial development. He has authored or coauthored over 150 scientific publications, including over 90 peer-reviewed original research articles. He is a member of the European Academy of Arts and Sciences, has served as ASCO program committee chair and co-chair for the NCI Ovarian Cancer Clinical Trials Planning Group and member of the NCCN ovarian cancer consensus panel

SPEAKERS



Joyce Liu, MD, MPH

Associate Professor of Medicine at Dana Farber Cancer Institute (DFCI) and Harvard Medical School

Dr. Liu is an Associate Professor of Medicine at Dana Farber Cancer Institute (DFCI) and Harvard Medical School, where she is a medical oncologist specializing in gynecologic cancers. She is the Associate Chief and Director of Clinical Research for the Division of Gynecologic Oncology at DFCI and the Associate Clinical Research Officer for DFCI. Dr. Liu received her MD from Harvard Medical School and her MPH from the Harvard School of Public Health and completed her medical oncology fellowship at DFCI. Dr. Liu's research focuses on identifying and validating novel therapies for gynecologic cancers. She has led multiple clinical trials ranging from first-in-human trials of novel agents to international Phase 3 studies. She has received grant support from the National Cancer Institute, the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), and the Ovarian Cancer Research Fund Alliance. She is the vice chair of the NRG Ovarian Cancer Subcommittee and currently chairs the NCCN Ovarian Cancer Panel, and she has also served on several ASCO guideline committees.



Cara Mathews, MD

Associate Professor, Obstetrics and Gynecology
Warren Alpert Medical School of Brown University
Gynecologic Oncologist
Women & Infants Hospital
Legorreta Cancer Center

Dr. Cara Mathews is an Associate Professor of Obstetrics and Gynecology at the Warren Alpert Medical School of Brown University and a practicing gynecologic oncologist at Women & Infants Hospital of Rhode Island and the Legorreta Cancer Center. She earned her undergraduate and medical degrees from Dartmouth College and Dartmouth Medical School, followed by residency training in Obstetrics and Gynecology at Women's & Infants Hospital/Brown University and a fellowship in Gynecologic Oncology at the University of Oklahoma Health Sciences Center. Upon returning to Women & Infants, Dr. Mathews established an early-phase clinical trial program focused on gynecologic and breast cancers, incorporating both NCTN and industry-sponsored studies. She currently serves as Director of Oncology Research and the NRG Oncology Principal Investigator at Women & Infants Hospital.

SPEAKERS



Kari Ring, MD

Associate Professor of Obstetrics and Gynecology
University of Virginia

Dr. Ring is an Associate Professor of Obstetrics and Gynecology and practices full spectrum gynecologic oncology at the University of Virginia.

She graduated from Washington and Lee University and received her medical degree at the University of Virginia School of Medicine. She remained in Charlottesville, where she completed residency training in obstetrics and gynecology at UVA. She then completed fellowship training in gynecologic oncology at The University of Texas MD Anderson Cancer Center. In addition to treating patients with gynecologic cancers, Dr. Ring has an interest in clinical trials and hereditary cancers and is director of the Hereditary Cancer Program as well as the Li Fraumeni Program at UVA. She is actively involved in prevention trials with a focus on geographically underserved patient populations.



le-Ming Shih, MD, PhD

Richard W. TeLinde Distinguished Professor
Department of Gynecology and Obstetrics
Co-Director, Women Malignancies Program
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine

Dr. le-Ming Shih is the Richard W. TeLinde Distinguished Professor of Gynecologic Pathology in the Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine. He is also the director of the TeLinde inter-departmental gynecologic disease research program and a co-director of the Women's Malignancy Group at the Sidney Kimmel Comprehensive Cancer Center. Originally from Taiwan, he moved to the U.S. to pursue a PhD degree at the University of Pennsylvania. He completed his training at the Johns Hopkins Hospital. After finishing a residency, clinical fellowship, and research fellowship at Hopkins, he became a faculty member there in 2000. Dr. Shih has served as an attending pathologist at the Johns Hopkins Hospital, with clinical expertise in ovarian cancer, uterine cancer, endometriosis, and gestational trophoblastic diseases. His research focuses on understanding the diagnostic, molecular, and pathogenic aspects of various gynecologic cancers. The research findings from his team have contributed to establishing the tubal paradigm in the genesis of ovarian serous carcinoma and have led to a new hypothesis in the pathogenesis of endometriosis.

Additionally, he is a dedicated educator, mentoring students, fellows, junior faculty, and pathologists worldwide. He has served on various advisory boards, and currently, Dr. Shih is a senior editor of AACR Cancer Research and an editorial member of the recent World Health Organization (WHO) Classification of Female Genital Tumors.

SPEAKERS

le-Ming Shih Bio Continued

Over the past two decades, his research has received continuous support from the NIH/NCI, the US Department of Defense Ovarian Cancer Research Program, and several private foundations. As supported by these research grants, he has dedicated himself to advancing next-generation pathology research and innovation by integrating morphology, spatial technologies, single-cell analysis, micro-omics, and computational/AI tools.

Dr. Shih has published over 410 peer-reviewed research articles in NEJM, Cancer Cell, PNAS, Science, Lancet Oncology, Nature, and Nature Medicine. He received the Rosalind Franklin Prize for Excellence in Ovarian Cancer and the NIH Specialized Program of Research Excellence award.



Fiona Simpkins, MD

Hilarie and Michell Morgan President's Distinguished Professor
Director, Clinical & Translational Gynecology Oncology Research
Penn Medicine Health System
Division of Gynecology Oncology
University of Pennsylvania

Dr. Simpkins, MD is a Professor in the Division of Gynecology Oncology and Department of OB-GYN at the University of Pennsylvania (UPENN). She is Director of Clinical and Translational Research for Penn Medicine Health System and Co-Principal Investigator (PI) for The Center of Excellence for Ovarian Cancer (TCE) at the Abramson Cancer Center at UPENN. She also is a member of the Phase I/Developmental Therapeutics Committee for gynecological cancers and the UPENN Phase I PI for the NRG Cooperative Group. Dr. Simpkins completed her OB-GYN residency at Johns Hopkins University and Gynecology Oncology fellowship at the Cleveland Clinic Foundation. She completed a Cancer Research Training fellowship focusing on ovarian cancer signal transduction at the National Cancer Institute and a post-doctoral fellowship investigating anti-estrogen resistance in ovarian cancer. She is a translational scientist and the overarching goal of her laboratory is to identify novel strategies to overcome drug resistance, such as PARP inhibitor and platinum resistance, in ovarian cancer and bring these new findings to the clinic. Her laboratory has developed a preclinical drug development platform which is comprised of organoids and >100 patient-derived xenografts from ovarian and uterine tumors which have been characterized by genomics and proteomics. She is using this platform to identify biomarkers predicting responses to targeted therapies and to optimize strategies to overcome drug resistance. She has moved several therapies identified in the laboratory into Phase I/II clinical trials. Ultimately, Dr. Simpkins' goal is to bring therapies with strong preclinical evidence learned in her laboratory to the clinic via biomarker focused phase I/II/III clinical trials



Rebecca Stone, MD

Associate Professor
Division Director Gyn Oncology
Johns Hopkins SOM

Dr. Stone, MD, MS is Associate Professor and Director of Gynecologic Oncology at Johns Hopkins Medicine. She holds a joint appointment in the Armstrong Institute for her leadership in surgical quality and safety and is a visiting professor at MIT in the Dept of Biological Engineering. She works as a surgeon-scientist, her research spans clinical care, quality improvement, translational science, and ovarian cancer prevention, with more than 100 publications and a nationally funded research portfolio. Dr. Stone has dedicated her career to advancing ovarian cancer prevention from scientific discovery to standard of care, with a particular focus on ensuring all patients are aware of and able to choose evidence-based prevention strategies. She leads the Outsmart Ovarian Cancer initiative through a partnership supported by Break Through Cancer Foundation and the American Cancer Society.

Commercial Support

The GOG Foundation would like to thank and acknowledge the following company for providing Independent Medical Education (IME) grant support associated with the 2026 Summer Symposium titled: Ovarian Cancer Prevention is Our Duty: When We Fail—Recurrence Mitigation and Treatment Strategies for Ovarian Cancer

AbbVie
Astrazeneca
Corcept
Eli Lilly
GSK
Verastem
LabCorp